AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience, and eye care. The company’s strategy has focused on delivering strong financial results, maximizing the benefits of the Allergan acquisition, advancing and investing in its pipeline, and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. AbbVie’s financial performance in 2022 included delivering worldwide net revenues of $58.1 billion, operating earnings of $18.1 billion, and cash flows from operations of $24.9 billion. The company commits substantial effort, funds, and resources to research and development, which is essential for maintaining operational flexibility and adapting to competitive pressures. AbbVie continues to experience lower new patient starts in certain products and markets due to external pressures such as the COVID-19 pandemic, which has necessitated modifications to business practices to ensure continuity of operations. The company has implemented an integration plan designed to reduce costs and optimize the combined organization, realizing $2.5 billion of annual cost synergies in 2022. AbbVie’s operations are subject to various risks, including the expiration or loss of patent protection, which could trigger competition from lower-priced generic or biosimilar products, thereby impacting revenues and operational performance. The successful discovery, development, manufacturing, and sale of biologics is a complex process that requires innovative technologies and robust quality assurance measures. The company’s reliance on third-party service providers for manufacturing and distribution introduces additional risks that could adversely affect its ability to deliver products efficiently. Furthermore, AbbVie must navigate a highly regulated environment that can impose significant costs and operational constraints, affecting its ability to respond to market demands effectively. The company’s strategic initiatives include leveraging its commercial strength and international infrastructure to ensure strong execution of new product launches while managing the impact of biosimilar erosion on existing products. AbbVie’s ability to attract, develop, and retain highly qualified personnel is critical to its success in developing and commercializing innovative medicines. The company’s financial flexibility is supported by strong operating cash flows, enabling it to invest in research and development and respond to future challenges. AbbVie’s commitment to organizational resilience is evident in its proactive measures to mitigate risks associated with supply chain disruptions, regulatory changes, and market volatility. The company continuously evaluates its operational strategies to enhance its adaptability and ensure long-term sustainability in a rapidly evolving business environment.